23 June 2022 
EMA/CHMP/473504/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Rayvow 
lasmiditan 
On 23 June 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a marketing authorisation for the medicinal product Rayvow, 
intended for the treatment of migraine. The applicant for this medicinal product is Eli Lilly Nederland B.V. 
Rayvow will be available as 50 mg, 100 mg and 200 mg film-coated tablets. The active substance of 
Rayvow is lasmiditan, a 5-hydroxytriptamine 1F (5-HT1F) receptor agonist (ATC code: N02CC), effecting a 
decrease of neuropeptide release and an inhibition of pain pathways. 
The benefits of Rayvow is its ability to reduce migraine pain. The most common side effects are dizziness, 
somnolence and fatigue. 
The full indication is: 
Rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or 
without aura in adults. 
Detailed recommendations for the use of this product will be described in the summary of product 
characteristics (SmPC), which will be published in the European public assessment report (EPAR) and 
made available in all official European Union languages after the marketing authorisation has been 
granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
